 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (May 2020) |
 | |
 | |
| Company type | Public |
|---|---|
| Nasdaq Stockholm: SOBI | |
| Industry | Pharmaceutical |
| Headquarters | Stockholm, Sweden |
Key people | |
| Products | Treatments in the areas of haematology, immunology and specialty care |
| Revenue | SEK 18.8 bn (2022)[1] |
| SEK 14.4 bn (2022)[1] | |
| Total assets | SEK 52.5 bn (2022)[1] |
| Total equity | SEK 26.5 bn (2022)[1] |
Number of employees | 1,600 (2022)[1] |
| Parent | Investor AB (34.7%)[1] |
| Website | sobi.com |
| Footnotes / references [1] | |
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.[2][3]
- ^ a b c d e f g "Annual and sustainability report 2022" (PDF). June 1, 2023.
- ^ "Annual and Sustainability Report 2020" (PDF). Sobi. Archived from the original (PDF) on 25 May 2021. Retrieved 25 May 2021.
- ^ "Swedish Orphan Biovitrum AB". www.bloomberg.com. Bloomberg. Retrieved 7 May 2020.